Mitsuhiro Kamimura

Randomized Phase III Trial of Erlotinib Versus Docetaxel As Second- or Third-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA)

Tomoya Kawaguchi, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2014 · 261 citations · Full text

Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second- or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who have wild-type or mutant epidermal growth factor receptor (EGFR): Docetaxel and Erlotinib Lung Cancer Trial (DELTA).

Yoshio Okano, Masahiko Ando, Kazuhiro Asami et al. · Journal of Clinical Oncology · 2013 · 39 citations

Advanced Nsclc, Medicine, Cancer Management +13

Irinotecan (CPT-11) in combination with weekly administration of cisplatin (CDDP) for non-small-cell lung cancer

Kunihiko Kobayashi, Ayako Shinbara, Mitsuhiro Kamimura et al. · Cancer Chemotherapy and Pharmacology · 1998 · 38 citations

Oncology, Non-small-cell Lung Cancer, Medicine +9

Real-world efficacy of anti-IL-5 treatment in patients with allergic bronchopulmonary aspergillosis

Katsuyoshi Tomomatsu, Hirotaka Yasuba, Takashi Ishiguro et al. · Scientific Reports · 2023 · 36 citations · Full text

Asthma, Inflammatory Lung Disease, Lung Inflammation +17

Clinical outcomes after initial treatment of methicillin-resistant <em>Staphylococcus aureus</em> infections

Nobuaki Shime, Nobuyuki Saito, Miya Bokui et al. · Infection and Drug Resistance · 2018 · 16 citations · Full text